BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-07-038000PMID 17210865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only.

  2007cited by this paper
• Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.

  2006cited by this paper
• Is it time to stop treating subsets of DLBCL with R-CHOP?

  2006cited by this paper
• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

  2006cited by this paper
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

  2005cited by this paper
• Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

  2005cited by this paper
• Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

  2004cited by this paper
• Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.

  2004cited by this paper
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

  2003cited by this paper
• Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

  2003cited by this paper
• Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

  2003cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.

  2002cited by this paper
• Rituximab May Overcome bcl-2–Associated Chemotherapy Resistance in Untreated Diffuse Large B-Cell Lymphomas

  2002cited by this paper
• Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells.

  2001cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper

• Introduction The importance of Myd 88 L 265 P mutation , clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia

  2016cites this paper
• The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.

  2016cites this paper
• Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

  2015cites this paper
• Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?

  2012cites this paper
• The role of BCL6 in lymphomas and routes to therapy

  2011influential citation
• Comparison of four prognostic scores in peripheral T-cell lymphoma.

  2011cites this paper
• Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era

  2010cites this paper
• Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification

  2009cites this paper
• Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.

  2008cites this paper
• Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.

  2008cites this paper
• The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma

  2007cites this paper
• Underlying mechanisms of hematologic malignancies revealed by gene expression profiling

  2006cites this paper